

a role in the clinical response of a patient to the drug or drug candidate;

(b) the second business partner provides to the first business partner samples of genetic material from individual patients within a clinical cohort of patients who have been administered said drug or drug candidate;

(c) the second business partner conveys to the first business partner data describing individual clinical responses of said individual patients to said drug or drug candidate;

(d) the first business partner conducts a haplotype analysis of the candidate genes in the samples of genetic material, said analysis including the identification of known haplotypes or haplotype pairs, or both, and optionally including the discovery of new haplotypes;

(e) the first business partner determines the associations between one or more haplotypes or haplotype pairs, or both, and the clinical responses of the patients in the cohort; and

(f) the first business partner discloses said associations to the second business partner.

185. (new) A method for members of a business partnership to discover, develop, and deliver pharmaceuticals, characterized in that:

(a) the business partnership comprises at least a first business partner and a second business partner;

(b) the first business partner identifies haplotypes for genes and/or other loci found in a diverse set of individuals and stores the identified haplotypes in a relational database designed for efficiently storing and searching genomic and clinical information;

(c) the first business partner conveys to the second business partner access to an

informatics application which comprises the relational database and algorithms designed to find correlations between haplotypes or haplotype pairs, or both, stored in the database and a clinical outcome; and

(d) the second business partner uses the informatics application for one or more research and development activities selected from the group consisting of: target validation, lead prioritization, lead optimization, design of clinical trials, and interpretation of clinical trials.

REMARKS

Support for new claim 184 is found in the specification at page 132, lines 30-35, where the roles of the first and second business partner in finding associations of haplotypes with clinical response are set forth. Association of haplotype pairs with clinical response is described on page 8, lines 12-30. Support for new claim 185 is found in the specification at page 128, lines 29-34 (business partnership for discovery, development and delivery of pharmaceuticals); page 129, lines 5-19 (identification of haplotype data, storage in a database, and access through informatics program); and at page 130, lines 17-21 (target validation, lead prioritization and optimization, design and development of clinical trials.)

An appendix showing the added claims is attached hereto.